发明名称 Solid-state form of celecoxib having enhanced bioavailability
摘要 The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
申请公布号 NZ513964(A) 申请公布日期 2004.01.30
申请号 NZ20000513964 申请日期 2000.12.06
申请人 PHARMACIA CORPORATION 发明人 HAGEMAN, MICHAEL J;HE, XIAORONG;KARARLI, TUGRUL T;MACKIN, LESLEY A;MIYAKE, PATRICIA J;ROHRS, BRIAN R;STEFANSKI, KEVIN J
分类号 C07D233/60;A61K9/14;A61K9/16;A61K9/20;A61K9/24;A61K9/26;A61K9/46;A61K9/48;A61K9/50;A61K31/34;A61K31/341;A61K31/352;A61K31/41;A61K31/415;A61K31/42;A61K31/44;A61K31/444;A61K45/00;A61K45/06;A61K47/32;A61K47/38;A61P1/00;A61P1/02;A61P1/04;A61P1/16;A61P3/10;A61P9/00;A61P9/10;A61P11/00;A61P11/06;A61P13/12;A61P15/00;A61P15/04;A61P17/00;A61P17/02;A61P17/06;A61P17/10;A61P19/02;A61P19/10;A61P21/00;A61P21/04;A61P25/00;A61P25/06;A61P25/28;A61P25/32;A61P27/02;A61P27/12;A61P29/00;A61P31/12;A61P31/18;A61P35/00;A61P37/08;A61P43/00;C07D213/61;C07D231/12;C07D261/08;C07D307/58;C07D311/58;(IPC1-7):C07D231/12 主分类号 C07D233/60
代理机构 代理人
主权项
地址